Funding_NN source_NN ,_, trial_NN outcome_NN and_CC reporting_VBG quality_NN :_: are_VBP they_PP related_VBN ?_SENT Results_NNS of_IN a_DT pilot_NN study_NN Abstract_NP |_SYM Background_NN |_SYM There_EX has_VBZ been_VBN increasing_VBG concern_NN regarding_VBG the_DT potential_JJ effects_NNS of_IN the_DT commercialization_NN of_IN research_NN ._SENT Methods_NNS |_SYM In_IN order_NN to_TO examine_VB the_DT relationships_NNS between_IN funding_NN source_NN ,_, trial_NN outcome_NN and_CC reporting_VBG quality_NN ,_, recent_JJ issues_NNS of_IN five_CD peer-reviewed_JJ ,_, high_JJ impact_NN factor_NN ,_, general_JJ medical_JJ journals_NNS were_VBD hand-searched_VBN to_TO identify_VB a_DT sample_NN of_IN 100_CD randomized_VBD controlled_JJ trials_NNS (_( 20_CD trials/journal_NN )_) ._SENT Relevant_JJ data_NNS ,_, including_VBG funding_NN source_NN (_( industry/not-for-profit/mixed/not_NN reported_VBN )_) and_CC statistical_JJ significance_NN of_IN primary_JJ outcome_NN (_( favouring_VBG new_JJ treatment/favouring_NN conventional_JJ treatment/neutral/unclear_NN )_) ,_, were_VBD abstracted_VBN ._SENT Quality_NN scores_NNS were_VBD assigned_VBN using_VBG the_DT Jadad_NP scale_NN and_CC the_DT adequacy_NN of_IN allocation_NN concealment_NN ._SENT Results_NNS |_SYM Sixty-six_NP percent_NN of_IN trials_NNS received_VBD some_DT industry_NN funding_NN ._SENT Trial_NN outcome_NN was_VBD not_RB associated_VBN with_IN funding_NN source_NN (_( p=_NN .461_CD )_) ._SENT There_EX was_VBD a_DT preponderance_NN of_IN favourable_JJ statistical_JJ conclusions_NNS among_IN published_VBN trials_NNS with_IN 67_CD %_NN reporting_VBG results_NNS that_WDT favored_VBD a_DT new_JJ treatment_NN whereas_IN 6_CD %_NN favoured_VBD the_DT conventional_JJ treatment_NN ._SENT Quality_NN scores_NNS were_VBD not_RB associated_VBN with_IN funding_NN source_NN or_CC trial_NN outcome_NN ._SENT Conclusions_NNS |_SYM It_PP is_VBZ not_RB known_VBN whether_IN the_DT absence_NN of_IN significant_JJ associations_NNS between_IN funding_NN source_NN ,_, trial_NN outcome_NN and_CC reporting_VBG quality_NN reflects_VBZ a_DT true_JJ absence_NN of_IN an_DT association_NN or_CC is_VBZ an_DT artefact_NN of_IN inadequate_JJ statistical_JJ power_NN ,_, reliance_NN on_IN voluntary_JJ disclosure_NN of_IN funding_NN information_NN ,_, a_DT focus_NN on_IN trials_NNS recently_RB published_VBN in_IN the_DT top_JJ medical_JJ journals_NNS ,_, or_CC some_DT combination_NN thereof_RB ._SENT Continued_VBN and_CC expanded_VBN monitoring_NN of_IN potential_JJ conflicts_NNS is_VBZ recommended_VBN ,_, particularly_RB in_IN light_NN of_IN new_JJ guidelines_NNS for_IN disclosure_NN that_WDT have_VBP been_VBN endorsed_VBN by_IN the_DT ICMJE_NP ._SENT There_EX has_VBZ been_VBN increasing_VBG concern_NN regarding_VBG the_DT potential_JJ effects_NNS of_IN the_DT commercialization_NN of_IN research_NN ._SENT This_DT concern_NN has_VBZ coincided_VBN with_IN the_DT reduced_VBN availability_NN of_IN public_JJ research_NN funds_NNS which_WDT has_VBZ ,_, in_IN turn_NN ,_, translated_VBN to_TO scientists_NNS '_POS increased_VBN reliance_NN on_IN industry_NN support_NN ._SENT For_IN example_NN ,_, in_IN the_DT United_NP States_NPS ,_, approximately_RB 70_CD %_NN of_IN clinical_JJ drug_NN trials_NNS are_VBP now_RB funded_VBN by_IN industry_NN ._SENT Industry_NN funding_NN of_IN biomedical_JJ research_NN can_MD be_VB viewed_VBN as_IN a_DT conflict_NN of_IN interest_NN because_IN the_DT sponsor_NN of_IN the_DT study_NN has_VBZ a_DT vested_JJ financial_JJ interest_NN in_IN its_PP$ outcome_NN ._SENT Since_IN even_RB the_DT perception_NN of_IN a_DT conflict_NN can_MD undermine_VB the_DT public_NN 's_POS trust_NN ,_, due_JJ diligence_NN ,_, in_IN the_DT form_NN of_IN recognizing_VBG and_CC managing_VBG potential_JJ conflicts_NNS ,_, is_VBZ warranted_VBN ._SENT This_DT is_VBZ not_RB to_TO suggest_VB that_DT industry_NN abandon_VB its_PP$ sponsorship_NN of_IN biomedical_JJ research_NN ._SENT Indeed_RB ,_, many_JJ medical_JJ discoveries_NNS may_MD not_RB have_VB occurred_VBN without_IN industry_NN funding_NN ._SENT Nevertheless_RB ,_, fundamental_JJ errors_NNS have_VBP been_VBN noted_VBN in_IN the_DT design_NN of_IN industry-funded_JJ trials_NNS ._SENT These_DT methodological_JJ deficiencies_NNS ,_, perhaps_RB operating_VBG in_IN conjunction_NN with_IN the_DT well-documented_JJ phenomenon_NN of_IN publication_NN bias_NN ,_, have_VBP led_VBN to_TO a_DT preponderance_NN of_IN published_VBN trials_NNS that_WDT have_VBP received_VBN funding_NN from_IN for-profit_JJ entities_NNS and_CC whose_WP$ conclusions_NNS favour_VBP industry_NN ._SENT Concern_NN over_IN the_DT increasing_VBG commercialization_NN of_IN research_NN also_RB extends_VBZ to_TO the_DT quality_NN of_IN reporting_NN ._SENT Low_JJ quality_NN reports_NNS have_VBP been_VBN noted_VBN among_IN published_VBN trials_NNS and_CC reports_NNS of_IN low_JJ quality_NN trials_NNS have_VBP been_VBN found_VBN to_TO exaggerate_VB an_DT intervention_NN 's_POS effectiveness_NN ._SENT Because_IN relationships_NNS between_IN funding_NN source_NN ,_, trial_NN outcome_NN and_CC reporting_NN quality_NN may_MD bias_VB study_NN results_NNS ,_, making_VBG informed_VBN decision_NN making_VBG about_IN the_DT merits_NNS of_IN an_DT intervention_NN more_RBR difficult_JJ for_IN clinicians_NNS and_CC consumers_NNS alike_RB ,_, it_PP is_VBZ important_JJ to_TO examine_VB the_DT extent_NN to_TO which_WDT a_DT trial_NN 's_POS source_NN of_IN funding_NN influences_VBZ its_PP$ results_NNS ._SENT A_DT convenience_NN sample_NN of_IN 100_CD randomized_VBD controlled_JJ trials_NNS (_( RCTs_NP )_) was_VBD identified_VBN by_IN hand-searching_VBG recent_JJ issues_NNS of_IN five_CD peer-reviewed_JJ ,_, high_JJ impact_NN factor_NN general_JJ medical_JJ journals_NNS (_( Annals_NP of_IN Internal_NP Medicine_NP ,_, British_NP Medical_NP Journal_NP ,_, Journal_NP of_IN the_DT American_NP Medical_NP Association_NP ,_, The_DT Lancet_NP ,_, The_DT New_NP England_NP Journal_NP of_IN Medicine_NP )_) ._SENT Issues_NNS published_VBN between_IN January_NP 1999_CD and_CC October_NP 2000_CD were_VBD searched_VBN until_IN 20_CD RCTs/journal_NP were_VBD identified_VBN ._SENT To_TO be_VB eligible_JJ for_IN inclusion_NN ,_, the_DT RCT_NP needed_VBD to_TO be_VB published_VBN as_IN a_DT full_JJ report_NN ._SENT Interventions_NNS were_VBD restricted_VBN to_TO pharmaceuticals_NNS ;_: medical_JJ devices_NNS ,_, surgical_JJ procedures_NNS and_CC methods_NNS of_IN medical_JJ management_NN (_( e.g._FW ,_, lifestyle_NN counseling_NN )_) were_VBD excluded_VBN ._SENT No_DT attempts_NNS were_VBD made_VBN to_TO limit_VB the_DT selection_NN to_TO any_DT particular_JJ RCT_NP design_NN ,_, number_NN of_IN treatment_NN arms_NNS ,_, comparator_NN (_( e.g._FW ,_, placebo_NN ,_, active_JJ control_NN ,_, alternate_JJ dosing_VBG ,_, herbal_JJ therapy_NN )_) ,_, study_NN population_NN or_CC disease_NN category_NN ._SENT Relevant_JJ data_NNS ,_, including_VBG funding_NN source(s)_NN and_CC primary_JJ outcome_NN ,_, were_VBD abstracted_VBN from_IN each_DT eligible_JJ RCT_NN ._SENT Reporting_VBG quality_NN was_VBD assessed_VBN using_VBG both_CC a_DT composite_JJ (_( overall_JJ score_NN on_IN the_DT Jadad_NP scale_NN )_) and_CC a_DT component_NN (_( individual_JJ items_NNS on_IN Jadad_NP scale_NN and_CC adequacy_NN of_IN allocation_NN concealment_NN )_) approach_NN ._SENT The_DT Jadad_NP scale_NN consists_VBZ of_IN a_DT total_NN of_IN five_CD items_NNS ;_: two_CD items_NNS relate_VBP to_TO blinding_NN ,_, two_CD items_NNS relate_VBP to_TO randomization_NN and_CC one_CD item_NN assesses_VBZ the_DT description_NN of_IN withdrawals/drop-outs_NNS ._SENT When_WRB using_VBG the_DT Jadad_NP scale_NN to_TO score_VB the_DT quality_NN of_IN a_DT trial_NN report_NN ,_, each_DT of_IN the_DT five_CD items_NNS receives_VBZ a_DT "_`` yes_UH "_'' or_CC a_DT "_`` no_RB ,_, "_'' resulting_VBG in_IN an_DT overall/composite_JJ quality_NN score_NN that_WDT can_MD range_VB from_IN 0_CD to_TO 5_CD ;_: higher_JJR scores_NNS reflect_VBP better_RBR methodological_JJ quality_NN ._SENT Allocation_NN concealment_NN was_VBD rated_VBN as_IN adequate_JJ ,_, inadequate_JJ or_CC unclear_JJ in_IN the_DT manner_NN proposed_VBN by_IN Schulz_NP et_CC al_NP ._SENT Allocation_NN concealment_NN refers_VBZ to_TO the_DT process_NN that_WDT prevents_VBZ foreknowledge_NN of_IN treatment_NN assignment_NN and_CC thus_RB ,_, shields_VBZ those_DT who_WP enroll_VBP participants_NNS from_IN being_VBG influenced_VBN by_IN this_DT knowledge_NN ._SENT For_IN example_NN ,_, a_DT trial_NN was_VBD rated_VBN as_IN having_VBG "_`` adequate_JJ "_'' concealment_NN if_IN allocations_NNS were_VBD performed_VBN using_VBG central_JJ randomization_NN ;_: numbered/coded_JJ bottles/containers_NNS ;_: serially_RB numbered_VBN ,_, opaque_JJ ,_, sealed_JJ envelopes_NNS or_CC if_IN the_DT formulations_NNS were_VBD prepared_VBN by_IN a_DT pharmacy_NN ._SENT Allocation_NN was_VBD classified_VBN as_IN "_`` inadequate_JJ "_'' if_IN assignments_NNS were_VBD made_VBN on_IN an_DT alternating_VBG basis_NN or_CC via_IN reference_NN to_TO case_NN record_NN number_NN or_CC date_NN of_IN birth_NN ._SENT Trials_NNS that_WDT received_VBD an_DT "_`` unclear_JJ "_'' rating_NN would_MD have_VB failed_VBN to_TO provide_VB sufficient_JJ information_NN regarding_VBG the_DT allocation_NN process_NN on_IN which_WDT to_TO base_VB our_PP$ decision_NN ._SENT In_IN all_DT cases_NNS ,_, reporting_VBG quality_NN was_VBD evaluated_VBN by_IN two_CD independent_JJ ,_, experienced_JJ reviewers_NNS (_( DM_NP ,_, TC_NP )_) ._SENT No_DT formal_JJ training_NN was_VBD conducted_VBN prior_RB to_TO evaluating_VBG the_DT RCTs_NP using_VBG either_RB of_IN the_DT quality_NN assessment_NN scales_NNS since_IN both_DT raters_NNS have_VBP extensive_JJ experience_NN using_VBG these_DT methods_NNS ._SENT Moreover_RB ,_, since_IN any_DT disagreements_NNS in_IN quality_NN ratings_NNS were_VBD resolved_VBN by_IN consensus_NN ,_, we_PP did_VBD not_RB undertake_VB assessment_NN of_IN inter-rater_NN reliability_NN ._SENT In_IN order_NN to_TO examine_VB the_DT relationship_NN between_IN trial_NN outcome_NN ,_, funding_VBG source_NN and_CC reporting_VBG quality_NN ,_, SPSS-PC_NP software_NN was_VBD used_VBN to_TO conduct_VB statistical_JJ analyses_NNS in_IN the_DT form_NN of_IN Fisher_NP 's_POS exact_JJ test_NN or_CC ANOVAs_NP ,_, as_RB appropriate_JJ ._SENT The_DT odds_NNS ,_, and_CC corresponding_JJ 95_CD %_NN confidence_NN intervals_NNS ,_, of_IN unclear_JJ allocation_NN concealment_NN ,_, by_IN funding_NN source_NN and_CC trial_NN outcome_NN ,_, are_VBP also_RB presented_VBN ._SENT Trials_NNS were_VBD classified_VBN according_VBG to_TO their_PP$ funding_NN source(s)_NN in_IN a_DT manner_NN similar_JJ to_TO that_DT used_VBN by_IN Rochon_NP ,_, permitting_VBG comparison_NN of_IN trials_NNS across_IN four_CD levels_NNS of_IN funding_NN :_: entirely_RB industry_NN ,_, entirely_RB not-for-profit_JJ ,_, mixed_JJ and_CC not_RB reported_VBD ._SENT A_DT trial_NN was_VBD classified_VBN as_IN having_VBG "_`` mixed_JJ "_'' funding_NN if_IN it_PP received_VBD support_NN from_IN at_IN least_JJS one_CD industry_NN source_NN and_CC at_IN least_JJS one_CD not-for-profit_JJ source_NN ._SENT Because_IN this_DT study_NN was_VBD restricted_VBN to_TO RCTs_NP that_WDT examined_VBD pharmaceuticals_NNS ,_, industry_NN funding_NN is_VBZ synonymous_JJ with_IN pharmaceutical_JJ company_NN funding_NN ._SENT The_DT primary_JJ outcome_NN was_VBD defined_VBN as_IN the_DT one_CD stated_VBN as_IN such_JJ by_IN the_DT authors_NNS or_CC ,_, if_IN there_EX was_VBD no_DT such_JJ statement_NN ,_, the_DT one_CD that_WDT was_VBD most_RBS clinically_RB relevant_JJ (_( i.e._FW ,_, mortality_NN over_IN morbidity_NN )_) ._SENT If_IN one_CD outcome_NN was_VBD not_RB more_RBR clinically_RB relevant_JJ than_IN the_DT others_NNS ,_, the_DT outcome_NN contributing_VBG the_DT most_JJS patients_NNS was_VBD used_VBN ._SENT On_IN the_DT basis_NN of_IN statistical_JJ interpretation_NN of_IN results_NNS ,_, rather_RB than_IN reliance_NN on_IN authors_NNS '_POS interpretations_NNS presented_VBD in_IN discussion/conclusion_NN sections_NNS ,_, the_DT outcome_NN of_IN trials_NNS was_VBD classified_VBN as_IN favoured_VBN new_JJ treatment_NN ,_, favoured_VBD conventional_JJ treatment_NN ,_, neutral_JJ (_( i.e._FW ,_, non-significant_NP )_) or_CC unclear_JJ ._SENT Of_IN the_DT 100_CD trials_NNS reviewed_VBN ,_, sixty-six_NN were_VBD funded_VBN in_IN whole_JJ or_CC in_IN part_NN by_IN industry_NN ;_: 6_CD did_VBD not_RB disclose_VB their_PP$ source_NN of_IN funding_NN ._SENT Of_IN these_DT same_JJ 100_CD trials_NNS ,_, 67_CD favoured_VBD the_DT new_JJ therapy_NN ,_, 6_CD favoured_VBD the_DT conventional_JJ treatment_NN ,_, 19_CD reported_VBD neutral_JJ findings_NNS while_IN ,_, in_IN eight_CD cases_NNS ,_, the_DT outcome_NN was_VBD classified_VBN as_IN unclear_JJ owing_VBG to_TO ambiguity_NN between_IN the_DT defined_VBN outcome_NN of_IN interest_NN and_CC data_NNS presented_VBN in_IN the_DT results_NNS section_NN ._SENT Results_NNS for_IN reporting_VBG quality_NN varied_VBD according_VBG to_TO the_DT dimensions_NNS of_IN quality_NN that_WDT were_VBD measured_VBN :_: the_DT overall/composite_JJ score_NN on_IN the_DT Jadad_NP scale_NN indicated_VBD that_IN 74_CD %_NN of_IN the_DT trials_NNS were_VBD of_IN higher_JJR quality_NN (_( scores_NNS of_IN 3_CD --_: 5_LS )_) with_IN a_DT mean_JJ score_NN of_IN 3.31_CD (_( SD_NP 1.19_CD )_) while_IN allocation_NN concealment_NN was_VBD found_VBN to_TO be_VB unclear_JJ in_IN close_NN to_TO 60_CD %_NN of_IN trials_NNS ._SENT The_DT results_NNS of_IN bivariable_JJ analyses_NNS examining_VBG associations_NNS between_IN allocation_NN concealment_NN and_CC funding_NN source_NN and_CC between_IN allocation_NN concealment_NN and_CC trial_NN outcome_NN are_VBP presented_VBN in_IN Table_NP ._SENT Odds_NNS ratios_NNS and_CC corresponding_JJ 95_CD %_NN CI_NP for_IN these_DT associations_NNS are_VBP also_RB presented_VBN ._SENT Data_NNS reflecting_VBG the_DT comparison_NN between_IN funding_NN source_NN and_CC trial_NN outcome_NN are_VBP presented_VBN in_IN Table_NP ._SENT In_IN none_NN of_IN these_DT cases_NNS were_VBD the_DT associations_NNS found_VBD to_TO be_VB statistically_RB significant_JJ ._SENT A_DT one-way_JJ ANOVA_NP also_RB failed_VBD to_TO demonstrate_VB statistical_JJ significance_NN between_IN the_DT overall/composite_JJ score_NN on_IN the_DT Jadad_NP scale_NN ,_, measured_VBN as_IN a_DT continuous_JJ variable_NN ,_, and_CC funding_NN source_NN (_( F_NP =_SYM 1.853_CD ;_: df_NN =_SYM 3_CD ;_: p_NN =_SYM .143_CD )_) ,_, trial_NN outcome_NN (_( F_NP =_SYM 1.003_CD ;_: df_NN =_SYM 3_CD ;_: p_NN =.395_NN )_) and_CC allocation_NN concealment_NN (_( F_NP =_SYM 1.319_CD ;_: df_NN =_SYM 2_CD ;_: p_NN =_SYM .272_CD )_) ._SENT The_DT absence_NN of_IN a_DT statistically_RB significant_JJ association_NN between_IN reporting_VBG quality_NN and_CC funding_NN source_NN and_CC between_IN reporting_VBG quality_NN and_CC trial_NN outcome_NN persisted_VBD when_WRB individual_JJ components_NNS of_IN the_DT Jadad_NP scale_NN (_( i.e._FW ,_, blinding_NN ,_, randomization_NN ,_, and_CC description_NN of_IN withdrawals/drop-outs_NNS )_) were_VBD examined_VBN ._SENT Table_NP 1_CD |_SYM Allocation_NN concealment_NN by_IN funding_NN source_NN and_CC by_IN trial_NN outcome_NN Table_NP 2_CD |_SYM Funding_NP source_NN by_IN trial_NN outcome_NN The_DT results_NNS of_IN this_DT pilot_NN study_NN failed_VBD to_TO document_VB any_DT association_NN between_IN funding_NN source_NN ,_, trial_NN outcome_NN and_CC reporting_VBG quality_NN among_IN a_DT sample_NN of_IN RCTs_NP that_WDT were_VBD recently_RB published_VBN in_IN the_DT top_JJ five_CD general_JJ medical_JJ journals_NNS ._SENT It_PP is_VBZ not_RB known_VBN whether_IN this_DT finding_NN (_( which_WDT has_VBZ been_VBN observed_VBN by_IN some_DT but_CC not_RB by_IN others_NNS )_) reflects_VBZ a_DT true_JJ absence_NN of_IN an_DT association_NN or_CC ,_, instead_RB ,_, represents_VBZ an_DT artefact_NN ,_, due_JJ to_TO limitations_NNS inherent_JJ in_IN this_DT ,_, a_DT pilot_NN study_NN ._SENT For_IN example_NN ,_, our_PP$ failure_NN to_TO detect_VB any_DT significant_JJ associations_NNS may_MD result_VB from_IN a_DT type_NN 2_CD error_NN that_WDT indicates_VBZ inadequate_JJ statistical_JJ power_NN ._SENT Although_IN our_PP$ results_NNS do_VBP not_RB even_RB hint_VB at_IN a_DT trend_NN (_( and_CC ,_, perhaps_RB ,_, reflect_VBP the_DT emphasis_NN now_RB placed_VBN on_IN disclosure_NN at_IN the_DT journals_NNS included_VBD in_IN our_PP$ sample_NN )_) ,_, the_DT potential_NN for_IN type_NN 2_CD error_NN is_VBZ real_JJ ,_, as_RB suggested_VBN by_IN the_DT width_NN of_IN the_DT confidence_NN intervals_NNS presented_VBN in_IN Table_NP ._SENT Our_PP$ estimates_NNS of_IN association_NN were_VBD based_VBN on_IN a_DT sample_NN size_NN that_IN ,_, while_IN relatively_RB small_JJ ,_, is_VBZ typical_JJ of_IN the_DT initial_JJ phases_NNS of_IN a_DT program_NN theme_NN ,_, such_JJ as_IN that_DT upon_IN which_WDT we_PP were_VBD embarking_VBG ;_: future_JJ works_NNS will_MD accrue_VB larger_JJR samples_NNS to_TO reduce_VB the_DT likelihood_NN of_IN this_DT error_NN ._SENT Admittedly_RB ,_, the_DT limitations_NNS of_IN our_PP$ study_NN extend_VB beyond_IN issues_NNS of_IN statistical_JJ power_NN ._SENT For_IN example_NN ,_, we_PP depended_VBD on_IN authors_NNS '_POS disclosure_NN of_IN a_DT trial_NN 's_POS funding_NN source(s)_NN and_CC the_DT subsequent_JJ publication_NN of_IN this_DT information_NN ._SENT Recent_JJ work_NN suggests_VBZ that_DT failure_NN to_TO disclose_VB personal_JJ financial_JJ conflicts_NNS is_VBZ widespread_JJ ._SENT Although_IN this_DT is_VBZ different_JJ than_IN reporting_VBG a_DT trial_NN 's_POS source_NN of_IN funding_NN ,_, it_PP supports_VBZ the_DT notion_NN that_IN failure_NN to_TO abide_VB by_IN journal_NN disclosure_NN requirements_NNS is_VBZ common_JJ ._SENT Moreover_RB ,_, since_IN journals_NNS ,_, themselves_PP ,_, do_VBP not_RB always_RB abide_VB by_IN their_PP$ own_JJ disclosure_NN rules_NNS ,_, our_PP$ categorization_NN of_IN funding_NN source(s)_NN may_MD be_VB biased_VBN ._SENT In_IN addition_NN ,_, because_IN this_DT study_NN focussed_VBN on_IN recent_JJ publications_NNS of_IN the_DT top_JJ five_CD general_JJ medical_JJ journals_NNS ,_, our_PP$ results_NNS may_MD not_RB generalize_VB to_TO journals_NNS that_WDT differ_VBP in_IN their_PP$ impact_NN factor_NN ,_, disclosure_NN requirements_NNS and/or_CC reporting_VBG policies_NNS ._SENT It_PP is_VBZ important_JJ that_IN our_PP$ results_NNS be_VB viewed_VBN in_IN this_DT context_NN ,_, particularly_RB since_IN some_DT research_NN suggests_VBZ that_IN researchers_NNS submit_VB their_PP$ "_`` best_JJS "_'' work_NN to_TO the_DT "_`` best_JJS "_'' journals_NNS ._SENT Future_JJ research_NN ,_, relying_VBG on_IN a_DT modified_JJ design_NN that_WDT has_VBZ been_VBN used_VBN to_TO address_VB similar_JJ questions_NNS might_MD allow_VB more_RBR comprehensive_JJ exploration_NN of_IN these_DT relationships_NNS ._SENT For_IN example_NN ,_, future_JJ works_NNS ,_, accruing_VBG a_DT larger_JJR sample_NN of_IN RCTs_NP from_IN a_DT wider_JJR variety_NN of_IN journals_NNS ,_, should_MD adjust_VB for_IN covariates_NNS (_( e.g._FW ,_, number_NN of_IN sites_NNS involved_VBN ,_, number_NN of_IN treatment_NN arms_NNS ,_, sample_NN size_NN )_) in_IN multivariable_JJ models_NNS and_CC may_MD find_VB it_PP fruitful_JJ to_TO examine_VB statistical_JJ outcomes_NNS in_IN the_DT context_NN of_IN effect_NN size_NN ._SENT It_PP is_VBZ also_RB possible_JJ that_IN the_DT discordance_NN seen_VBN between_IN our_PP$ findings_NNS and_CC others_NNS stems_VBZ ,_, in_IN whole_NN or_CC in_IN part_NN ,_, from_IN differences_NNS in_IN the_DT operational_JJ definition_NN of_IN "_`` industry-sponsored_NN research_NN ._SENT "_'' More_RBR specifically_RB ,_, some_DT have_VBP categorized_VBN RCTs_NP that_WDT receive_VBP any_DT industry_NN funding_NN to_TO be_VB "_`` industry-sponsored_NN "_'' and_CC have_VBP compared_VBN this_DT category_NN with_IN those_DT RCTs_NP that_WDT are_VBP wholly_RB funded_VBN by_IN not-for-profit_JJ monies_NN ._SENT In_IN our_PP$ study_NN ,_, we_PP treated_VBD RCTs_NP that_IN received_VBN funding_NN from_IN one_CD or_CC more_JJR corporate_JJ sponsor_NN and_CC one_CD or_CC more_JJR not-for-profit_JJ sponsor_NN as_IN receiving_VBG "_`` mixed_JJ funding_NN "_'' while_IN the_DT category_NN "_`` industry_NN only_RB "_'' was_VBD reserved_VBN for_IN those_DT RCTs_NP that_WDT did_VBD not_RB receive_VB any_DT not-for-profit_JJ funds_NNS ._SENT It_PP is_VBZ important_JJ that_IN authors_NNS acknowledge_VBP the_DT potential_NN for_IN differences_NNS in_IN operational_JJ definitions_NNS of_IN funding_NN source_NN between_IN studies_NNS to_TO produce_VB discordant_JJ results_NNS ;_: this_DT can_MD be_VB best_RBS accomplished_VBN by_IN ensuring_VBG that_IN the_DT scheme_NN for_IN classifying_VBG trials_NNS according_VBG to_TO their_PP$ funding_NN source(s)_NN be_VB made_VBN explicit_JJ in_IN each_DT report_NN ._SENT As_IN a_DT result_NN of_IN these_DT limitations_NNS ,_, we_PP are_VBP unable_JJ to_TO conclude_VB ,_, with_IN a_DT high_JJ degree_NN of_IN confidence_NN ,_, that_IN the_DT absence_NN of_IN an_DT association_NN between_IN funding_NN source_NN ,_, trial_NN outcome_NN and_CC reporting_NN quality_NN that_WDT was_VBD documented_VBN in_IN this_DT study_NN reflects_VBZ a_DT benefit_NN of_IN strengthened_JJ disclosure_NN requirements_NNS at_IN the_DT top_JJ general_JJ medical_JJ journals_NNS ._SENT Our_PP$ results_NNS do_VBP ,_, however_RB ,_, suggest_VBP the_DT benefits_NNS of_IN one_CD particular_JJ standardized_JJ reporting_NN requirement_NN ,_, CONSORT_NP ._SENT Endorsement_NN of_IN CONSORT_NP by_IN the_DT International_NP Committee_NP of_IN Medical_NP Journal_NP Editors_NP (_( ICMJE_NP )_) may_MD have_VB contributed_VBN to_TO the_DT majority_NN (_( ~75_JJ %_NN )_) of_IN trial_NN reports_NNS receiving_VBG moderate-high_JJ quality_NN composite_JJ scores_NNS on_IN the_DT Jadad_NP scale_NN ._SENT This_DT has_VBZ not_RB always_RB been_VBN the_DT case_NN ,_, with_IN almost_RB uniformly_RB poor_JJ quality_NN found_VBN amongst_IN trials_NNS published_VBN prior_RB to_TO widespread_JJ adherence_NN to_TO CONSORT_NP [_SYM ,-_NN ,_, ]_SYM ._SENT There_EX is_VBZ still_RB room_NN for_IN improvement_NN ,_, however_RB ._SENT Recent_JJ revisions_NNS to_TO CONSORT_NP and_CC its_PP$ adoption_NN by_IN increasing_VBG numbers_NNS of_IN journals_NNS should_MD address_VB the_DT alarming_JJ dominance_NN of_IN "_`` unclear_JJ "_'' allocation_NN concealment_NN seen_VBN among_IN trials_NNS examined_VBN in_IN this_DT report_NN and_CC elsewhere_RB [_SYM ,,-_NN ]_SYM ._SENT The_DT persistence_NN of_IN a_DT preponderance_NN of_IN trial_NN reports_NNS favoring_VBG novel_JJ treatments_NNS ,_, however_RB ,_, remains_VBZ a_DT challenge_NN ._SENT Concerted_JJ and_CC continued_JJ efforts_NNS to_TO monitor_VB the_DT reporting_VBG quality_NN of_IN RCTs_NP ,_, to_TO ascertain_VB the_DT best_JJS method(s)_NN for_IN its_PP$ evaluation_NN and_CC to_TO encourage_VB the_DT mandatory_JJ registration_NN of_IN trials_NNS [_SYM ,,,-_NN ]_SYM are_VBP recommended_VBN ._SENT Given_VBN that_IN the_DT ICMJE_NP recently_RB strengthened_VBD its_PP$ requirement_NN for_IN disclosure_NN of_IN information_NN as_RB to_TO the_DT role(s)_NN of_IN study_NN sponsor(s)_NN in_IN all_DT aspects_NNS of_IN study_NN design_NN ,_, conduct_NN and_CC publication_NN while_NN ,_, at_IN the_DT same_JJ time_NN ,_, the_DT New_NP England_NP Journal_NP of_IN Medicine_NP has_VBZ announced_VBN that_IN they_PP will_MD be_VB relaxing_VBG their_PP$ longstanding_JJ rules_NNS on_IN conflict_NN of_IN interest_NN ,_, the_DT question_NN posed_VBN by_IN this_DT study_NN should_MD be_VB revisited_VBN to_TO allow_VB for_IN more_JJR definitive_JJ determination_NN of_IN the_DT impact_NN of_IN industry_NN sponsorship_NN on_IN biomedical_JJ research_NN ._SENT We_PP encourage_VBP journal_NN editors_NNS to_TO continue_VB to_TO work_VB together_RB in_IN order_NN to_TO reach_VB consensus_NN as_RB to_TO the_DT particulars_NNS of_IN reporting_VBG requirements_NNS ._SENT None_NN declared_VBD ._SENT TJC_NP and_CC DM_NP have_VBP participated_VBN sufficiently_RB in_IN the_DT work_NN to_TO take_VB public_JJ responsibility_NN for_IN the_DT whole_JJ content_NN ._SENT TJC_NP has_VBZ made_VBN substantial_JJ contributions_NNS to_TO the_DT intellectual_JJ content_NN of_IN the_DT paper_NN as_IN they_PP relate_VBP to_TO this_DT study_NN 's_POS conception_NN and_CC design_NN ,_, the_DT acquisition_NN of_IN data_NNS ,_, its_PP$ analysis_NN and_CC interpretation_NN ._SENT TJC_NP was_VBD responsible_JJ for_IN the_DT initial_JJ draft_NN of_IN the_DT manuscript_NN and_CC all_DT subsequent_JJ revisions_NNS ._SENT NB_NP assisted_VBD in_IN the_DT analysis_NN and_CC interpretation_NN of_IN the_DT data_NNS and_CC provided_VBN critical_JJ revisions_NNS of_IN the_DT manuscript_NN for_IN important_JJ intellectual_JJ content_NN ._SENT DM_NP provided_VBD the_DT impetus_NN for_IN the_DT study_NN 's_POS conception_NN and_CC design_NN ,_, participated_VBN in_IN the_DT analysis_NN and_CC interpretation_NN of_IN data_NNS ,_, provided_VBD feedback_NN on_IN initial_JJ drafts_NNS of_IN the_DT manuscript_NN and_CC ,_, via_IN administrative_JJ supervision_NN ,_, also_RB permitted_VBN TC_NP and_CC NB_NP the_DT time_NN to_TO carry-out_JJ this_DT work_NN ._SENT All_DT authors_NNS have_VBP read_VBN and_CC approved_VBN the_DT final_JJ manuscript_NN ._SENT publication_NN history_NN :_: The_DT pre-publication_NN history_NN for_IN this_DT paper_NN can_MD be_VB accessed_VBN here_RB :_: 